Technology Appraisal Virtual Committee Meeting

Committee B

Zoom

# Minutes: Confirmed

## Date and Time: Thursday 16 July 2020 09.00am - 4.30pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Laura Bojke Present for all notes
4. Mr Mark Chapman Present for all notes
5. Dr Susan Faulds Present for all notes
6. Dr Mark Glover Present for all notes
7. Dr Megan John Present for all notes
8. Professor Sanjay Kinra Present for all notes
9. Dr Nicholas Latimer Present for all notes
10. Dr Veline L'Esperance Present for all notes
11. Dr Rhiannon Owen Present for all notes
12. Ms Anna Pracz Present for all notes
13. Dr Stephen Smith Present for all notes
14. Professor Nicky Welton Present for all notes
15. Mr Nigel Westwood Present for all notes
16. Professor Sarah Wild Present for all notes
17. Dr Ed Wilson Present for all notes
18. Dr Stuart Williams Present for notes 9 to 14
19. Mr Tony Wootton Present for all notes

### In attendance:

* Nicole Elliot, Associate Director, NICE, Present for notes 1 to 8
* Linda Landells, Associate Director, NICE, Present for notes 9 to 14
* Joanne Ekeledo, Project Manager, NICE, Present for notes 1 to 8
* Jeremy Powell, Project Manager, NICE, Present for notes 1 to 4 and 9 to 14
* Mira Patel, Administrator, NICE, Present for notes 1 to 4 and
* Laura Marsden, Coordinator, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for notes 1 to 4 and 9 to 14
* Natalie Spray, Project Manager, NICE, Present for all notes
* Oswin Jackson, Digital Services, NICE, Present for notes 1 to 4
* Nick Lowe, Digital Services, NICE, Present for notes 9 to 10
* Mary Hughes, Technical Analyst, NICE, Present for notes 1 to 8
* Carl Prescott, Technical Adviser, NICE, Present for notes 1 to 8
* Alan Moore, Technical Analyst, NICE, Present for notes 9 to 14
* Emily Eaton Turner, Technical Adviser, NICE, Present for notes 9 to 14
* Caroline Farmer, PenTAG, Evidence Review Group, Present for notes 1 to 4
* G.J. Melendez-Torres, PenTAG, Evidence Review Group, Present for notes 1 to 4
* David Alexander Scott, PenTAG, Evidence Review Group, Present for notes 1 to 4
* Matt Stevenson, ScHARR, Evidence Review Group, Present for notes 9 to 11
* Aline Navega-Biz, ScHARR, Evidence Review Group, Present for notes 9 to 11
* John Stevens, ScHARR, Evidence Review Group, Present for notes 9 to 11
* Professor Peter Clarke, Cancer Drugs Fund, Present for notes 9 to 14

### Non-public attendees:

* Helen Barnett, Senior Editor, NICE, Present for notes 1 to 8
* Henry Edwards, Technical Advisor, Managed Access, NICE, Present for all notes
* Ann Greenwood, Senior Editor, NICE, Present for notes 9 to 14
* Claire Hawksworth, Technical Adviser, Managed Access, NICE, Present for all notes
* Edgar Masanga, Business Analyst, NICE, Present for all notes
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 1 to 4 and 9 to 10
* George Millington, Technical Analyst, NICE, Present for notes 9 to 14
* Catherine Pank, Corporate Office Coordinator, NICE, Present for notes 1 to 4 and 9 to 10
* Thomas Strong, Technical Adviser, Managed Access, NICE, Present for all notes
* Sharlene Ting, Technical Analyst, NICE, Present for notes 1 to 8
* Ross Wilkinson, Assistant Technical Analyst, NICE, Present for notes 9 to 14

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Wednesday 13 May 2020.

## Appraisal of caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

### Part 1 – Open session

1. The Chair welcomed the Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Sanofi.
2. The Chair asked all committee members, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Prior to the meeting Peter Wheatley Price declared a direct financial interest as he works for Takeda who are in phase 3 of producing a potential competitor product for caplacizumab.
      1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
   2. No further conflicts of interest were declared for this appraisal.
   3. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
   4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, ERG/AG representatives and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID1477]

### Part 1 – Open session

1. The Chair welcomed the invited Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Sanofi.
2. The Chair asked all committee members, ERG representatives and NICE staff present to declare any relevant interests.

10.1 Prior to the committee meeting Peter Wheatley-Price declared a direct financial interest as he works for Takeda who manufacture a potential competitor product for isatuximab.

10.1.1 It was agreed that this declaration would prevent him from participating in this section of the meeting.

* 1. No further conflicts of interest were declared for this appraisal
  2. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
  3. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.